This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Leigh-Perrots | |
|---|---|
| Name | Leigh-Perrots |
| Specialty | Neurology |
Leigh-Perrots is a rare neurodegenerative syndrome characterized by progressive neurological decline and multisystem involvement described in clinical case series and case reports. It has been discussed in literature alongside disorders such as Leigh syndrome, Perrault syndrome, Kearns–Sayre syndrome, Wernicke encephalopathy, and Friedreich's ataxia, and has been evaluated in contexts involving mitochondrial medicine, pediatric neurology, and metabolic genetics. Publications in journals associated with institutions like Mayo Clinic, Johns Hopkins Hospital, Great Ormond Street Hospital, Massachusetts General Hospital and consortia such as the European Reference Network have summarized phenotypes and diagnostic approaches.
Leigh-Perrots denotes a clinicopathologic entity defined by progressive subcortical and brainstem dysfunction with variable systemic features reported in cohorts from centers including Cambridge University Hospitals, University College Hospital, The Hospital for Sick Children (Toronto), and Baylor College of Medicine. Case descriptions have linked Leigh-Perrots to biochemical abnormalities observed in studies at National Institutes of Health, Institut Pasteur, Karolinska Institutet, and Imperial College London. Etiologic considerations have invoked defects in mitochondrial oxidative phosphorylation as described in work from University of California, San Francisco, University of Pennsylvania, Charité – Universitätsmedizin Berlin, and metabolic analyses performed at The Francis Crick Institute.
Patients with Leigh-Perrots typically present in infancy or childhood with signs comparable to those in Leigh syndrome, Ataxia telangiectasia, Rett syndrome, Angelman syndrome, and Spinal muscular atrophy, including psychomotor regression, hypotonia, movement disorders, and respiratory compromise. Neurologic, ophthalmologic, audiologic, and cardiologic evaluations often reference guidelines from American Academy of Neurology, American College of Medical Genetics and Genomics, European Society of Paediatric Radiology, Royal College of Paediatrics and Child Health, and World Health Organization for structured assessment. Magnetic resonance imaging patterns resembling lesions reported in Basal ganglia infarction, Pontine tegmentum lesions, Cerebellar degeneration, and metabolic profiles paralleling findings in mitochondrial complex I deficiency are reported by diagnostic centers such as Great Ormond Street Hospital, Vall d'Hebron University Hospital, and Hospital Sant Joan de Déu.
Genetic investigations have implicated variants in nuclear and mitochondrial genes previously associated with syndromes cataloged by OMIM, ClinVar, Human Gene Mutation Database, and research consortia including the 100,000 Genomes Project, gnomAD, and Exome Aggregation Consortium. Candidate loci discussed in parallel literature include genes encoding components of the respiratory chain studied at Cold Spring Harbor Laboratory, Sanger Institute, Max Planck Institute for Molecular Genetics, and National Human Genome Research Institute. Inheritance patterns reported echo those in mitochondrial inheritance, autosomal recessive inheritance, autosomal dominant inheritance, compound heterozygosity, and de novo mutation paradigms, with genetic counseling models referenced from National Society of Genetic Counselors and European Society of Human Genetics.
Pathophysiologic models draw on mechanistic frameworks developed for oxidative phosphorylation, mitochondrial DNA depletion, electron transport chain complex I dysfunction, reactive oxygen species, and apoptosis studied at research centers including Harvard Medical School, Stanford University School of Medicine, Yale School of Medicine, and University of Toronto. Mitochondrial bioenergetic failure leading to focal necrotic lesions in the basal ganglia and brainstem has been correlated with metabolic derangements measured in laboratories at University of Cambridge Metabolic Unit, Sidra Medicine, and Children's Hospital of Philadelphia. Secondary pathways involving lactate accumulation, pyruvate dehydrogenase complex dysfunction, and disruptions in mitochondrial fusion and fission proteins have been explored in publications from Max Planck Institute for Biology of Ageing and Weizmann Institute of Science.
Management strategies align with multidisciplinary protocols used for Leigh syndrome and related disorders at centers such as Johns Hopkins Hospital, Boston Children's Hospital, Children's Hospital of Philadelphia, Great Ormond Street Hospital, and Sheba Medical Center and involve supportive care, metabolic therapies, and symptomatic interventions described by societies including American Academy of Pediatrics and European Paediatric Neurology Society. Therapeutics evaluated in analogous conditions—such as cofactor supplementation, ketogenic dietary approaches used in epilepsy programs at Seattle Children's Hospital, and experimental gene therapy trials coordinated by National Institutes of Health Clinical Center and European Commission initiatives—inform off-label and investigational use. Prognosis is frequently guarded, reflecting outcomes reported in cohort studies from Mayo Clinic, University College London Hospitals, Royal Brompton Hospital, and long-term follow-up registries maintained by European Genetic Disease Network.
Epidemiologic data derive from case series and registries compiled by institutions including National Institutes of Health, Centers for Disease Control and Prevention, Public Health England, Agence Régionale de Santé, and academic centers such as University of Oxford and University of Edinburgh. The syndrome's characterization evolved through clinical observations published in journals associated with Lancet Neurology, New England Journal of Medicine, Journal of Pediatrics, Annals of Neurology, and Brain, with early descriptive reports emerging from collaborations among investigators at Addenbrooke's Hospital, Great Ormond Street Hospital, University of Zurich, and Hôpital Necker–Enfants Malades. Ongoing research is coordinated via networks including the European Reference Network, International Consortium on Mitochondrial Diseases, Rare Diseases Clinical Research Network, and patient advocacy organizations such as MitoAction and United Mitochondrial Disease Foundation.